Harpoon Therapeutics Inc (HARP) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Harpoon Therapeutics is on course to become a wholly-owned subsidiary of Merck, following a merger agreement reached earlier this year. With the critical Hart-Scott-Rodino antitrust waiting period having expired, the deal’s finalization now hinges on other customary conditions, including approval by Harpoon’s stockholders at an upcoming special meeting. Investors are encouraged to peruse the detailed proxy statement and other relevant materials filed with the SEC to understand the implications of the merger, available through various investor relations channels.
For further insights into HARP stock, check out TipRanks’ Stock Analysis page.
